ValiRx plc (AIM:VAL)

Market Cap	1.23M -45.3%
Revenue (ttm)	31.37K -37.0%
Net Income	-2.23M
EPS	-0.01
Shares Out	767.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.1615
Previous Close	0.1600
Day's Range	0.1500 - 0.1700
52-Week Range	0.1500 - 0.8485
Beta	-0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 3, 2026

About ValiRx

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 14
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VAL

Financial Performance

In 2025, ValiRx's revenue was 31,372, a decrease of -36.97% compared to the previous year's 49,775. Losses were -2.23 million, 16.5% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 6, 2026

Data Sources Report a data error